Xeligekimab in moderate to severe plaque psoriasis

In this study of 420 Chinese patients, researchers evaluated the efficacy and safety of xeligekimab in moderate to severe plaque psoriasis. Xaligekimab is a selective IL-17 inhibitor. Patients were randomized to receive xeligekimab 200 mg every 2 weeks or placebo for an initial period of 12 weeks. Treatment was then continued every 4 weeks for a further 40 weeks. At week 12, PASI scores 75, 90 and 100 were achieved in 90.7%, 74.4% and 30.2% of xeligekimab-treated patients, compared with 8.6%, 1.4% and 0% in the placebo group. No unexpected adverse events were observed.